Published Online: Tuesday, May 1, 2007

State pharmacy boards could lose their authority to regulate pharmacist compounding activities under a controversial new legislative plan being hammered out on Capitol Hill. The proposal, still in draft form at press time, was being circulated by a bipartisan group of senators headed by Senate Committee on Health, Education, Labor, and Pensions Chairman Edward Kennedy (D, Mass).

Under the plan, responsibility for regulating drug compounding would shift to the FDA—an agency that has shown little appreciation for the traditional right of pharmacists to compound medicines. The National Community Pharmacists Association and several other national and state pharmacy groups are urging federal lawmakers to reject this legislative proposal and support pharmacy's long-standing authority to compound drugs.

Visit ePharmacy Times at for a related article about the pharmacy organizations'concerns.

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues